The estimated Net Worth of Jonathan Slonin is at least $2.41 Millón dollars as of 1 August 2024. Dr Slonin owns over 945 units of Pacira BioSciences Inc stock worth over $1,225,978 and over the last 3 years he sold PCRX stock worth over $371,394. In addition, he makes $815,252 as Chief Clinical Officer at Pacira BioSciences Inc.
Dr has made over 8 trades of the Pacira BioSciences Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he sold 945 units of PCRX stock worth $18,947 on 1 August 2024.
The largest trade he's ever made was selling 5,012 units of Pacira BioSciences Inc stock on 11 June 2024 worth over $143,193. On average, Dr trades about 1,213 units every 73 days since 2021. As of 1 August 2024 he still owns at least 94,306 units of Pacira BioSciences Inc stock.
You can see the complete history of Dr Slonin stock trades at the bottom of the page.
Dr. Jonathan Slonin M.D. is the Chief Clinical Officer at Pacira BioSciences Inc.
As the Chief Clinical Officer of Pacira BioSciences Inc, the total compensation of Dr D at Pacira BioSciences Inc is $815,252. There are 10 executives at Pacira BioSciences Inc getting paid more, with David Stack having the highest compensation of $5,806,430.
Dr D is 46, he's been the Chief Clinical Officer of Pacira BioSciences Inc since . There are 23 older and 1 younger executives at Pacira BioSciences Inc. The oldest executive at Pacira BioSciences Inc is Gary Pace, 72, who is the Independent Director.
Jonathan's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.
Over the last 14 years, insiders at Pacira BioSciences Inc have traded over $321,391,130 worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth $15,133,188 . The most active insiders traders include Advisors Llc Orbi Med Capit..., Carl L Gordon y Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of $491,036. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth $20,034.
pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.
Pacira BioSciences Inc executives and other stock owners filed with the SEC include: